Table 4.

Candidate drugs for treating dyslipidemia and expected effects on key elements of the lipid profile

Drug class	Candidate drugs	TG %Δ	LDL-C %Δ	HDL-C %Δ
HMG-CoA reductase inhibitors: “Statins”	• Atorvastatin (Lipitor, New York, NY)	↓ 10–30	↓ 25–55	↑ 5–15
	• Lovastatin (Mevacor, Whitehouse Station, NJ, USA)
	• Pravastatin (Pravacol, Princeton, NJ)
	• Rasuvastatin (Crestor, Wilmington, DE)
	• Simvastatin (Zocor, Whitehouse Station, NJ, USA)
Cholesterol uptake blocker	• Ezetimibe (Zetia, Whitehouse Station, NJ, USA)	↓ 5–15	↓ 15–20	–
Bile–acid sequestrates	• Cholestyramine (Questran, Spring Valley, NY)	↑↓ 10–20	↑↓ 20–20	–
	• Colesevelam (Welchol, Parsippany, NJ)
	• Colestipol (Colestid, New York, NY)
Niacin extended release	• Niaspan, Abbott Park, IL, U.S.A.	↓ 10–30	↓ 5–25	↑ 10–35
Fibrates		↓ 30–50	↓0–15	↑5–20
	• Tricor (Fenofibrate, Abbott Park, IL)
	• Lopid (Gemfibrozil, New York, NY)
Omega-3 fat*		↓30–50	↓5–15	↓5–10

*3.8 g daily dose.